Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.
There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD. With question to test your knowledge.
What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video. With question to test your knowledge.
Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options. With question to test your knowledge.
Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.
5 Things a cardiologist needs to know about GLP-1 RA Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.
5 Things a cardiologist needs to know about GLP-1RA Prof. Verma discusses the CV results of clinical trials with GLP-1RAs and how these translate to CV protection in T2DM.
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.
AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.
5 Things a cardiologist needs to know about GLP-1RA Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.
There are barriers to intensify treatment in T2DM patients, leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. In this presentation, prof. Hobbs discusses the classic CV risk factors one by one.
Prof. Landmesser gives an introduction to the symposium about managing diabetes in CV risk reduction, that was held during the virtual ESC 2020 congress.
Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.
Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.
ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.
ACC 2020 COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.
Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment in T2DM patients with peripheral artery disease.
DIabetes summit Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.
Diabetes summit Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.
Diabetes summit Prof. Lehmann considers factors that may play a role when diabetes guidelines are not adequately implemented, and how these barriers may be overcome.
Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.
Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.
CSI Paris Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.
Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.
Before listing the differences between the AHA/ACC 2018 and ESC/EAS 2019 dyslipidemia guidelines, prof. Ballantyne shares common themes and shared concept across the guidelines.
ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.
Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.
Prof. Ray describes the high residual CV risk in post-ACS diabetes patients, and how BET inhibition with apabetalone may reduce this residual risk and thereby prevent CV events.
ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.
Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.
ESC 2019 The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.
ESC 2019 In diabetes patients with stable CAD, ticagrelor plus aspirin resulted in reduced CV outcomes, but at the cost of increased bleeding. Net clinical benefit was favorable in a prespecified subgroup of patients with prior PCI.
Prof. Knop describes the possible mechanisms of CV/CKD risk reduction by GLP-1 receptor activation.
Paola Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.
Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.
We have entered a new era for treatment of cardiorenal disease in diabetes. Prof. John Deanfield discusses evidence on the need for early management and alteration of upstream factors that affect renal and cardiac function in diabetic patients.
Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.
Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.
Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.
EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how we can modify CVD risk factors in these patients.
EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.
Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.
ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.
What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.
ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.
ISN-WCN 2019 Use of canagliflozin in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.
ISN-WCN 2019 Prof. Hiddo Lambers Heerspink dissusses the unique design of the SONAR trial and the findings with atrasentan therapy in patients with diabetic kidney disease.
ISN-WCN 2019 The SONAR trial was designed to safely test the effect of atrasentan in a selected group of high-risk T2DM patients with kidney disease. This proved to be a good approach, as results were very positive.
ICN-WCN 2019 Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.
Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.
Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.
Prof. Neil Poulter discusses lessons that can be drawn from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.
Prof. Lina Badimon discusses several lines of evidence on the beneficial effects of novel antidiabetic therapeutic strategies that affect multiple body systems in addition to glucose metabolism.
Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .
Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.
Different GLP-1RAs have shown different effects in CV outcomes trials. Prof Rydén scrutinizes the results of the trials to learn more about the effects of individual GLP-1RAs and what the differences may originate from.
AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.
Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
ESC 2018 Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.
ESC 2018 In overweight or obese patients with CVD or diabetes with CV risk factors, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the details of the CAMELLIA-TIMI 61 trial.
ESC 2018 Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.
Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.
Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.
Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.
Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.
A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.
Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Charlotte Koopal discusses the pathofysiology of familial dysbetalipoproteinemia, how to diagnose the disease and recommendations for treatment.
Three cardiology and diabetes experts speculate on how GLP-1 RAs and SGLT2 inhibitors may be benefitted from to lower CV risk, beyond treatment of T2DM patients. Also; may they be used simultaneously?
Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.
Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management of these patients.
Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.
5 Things a cardiologist needs to know about diabetes Several factors make a diabetes patient more vulnerable to severe hypoglycemia events, which are associated with higher CV morbidity and mortality. Prof Schernthaner discusses how hypoglycemia can be prevented.
5 Things a cardiologist needs to know about diabetes Multiple causal pathways contribute to development of T2DM, thus various processes may be targeted to improve glucose regulation. Prof. Bailey briefly summarises the available therapeutic options.
5 Things a cardiologist needs to know about diabetes Prof Leiter gives an update of the trials on new antihyperglycemic drugs (DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors) that have been completed or are ongoing since the FDA mandated demonstration of CV safety.
5 Things a cardiologist needs to know about diabetes Prof Naveed Sattar discusses the value of HbA1c to diagnose T2DM, and how HbA1c levels are related to the risk of developing micro and macrovascular disease and the consequences thereof for choosing a HbA1c therapeutic target.
5 Things a cardiologist needs to know about diabetes Prof. Ray focuses on micro- and macrovascular disease in type 2 diabetes, their implications, their interrelationship and how these risks can be modified by new glucose-lowering agents.
Dr. Aruna Pradhan describes the role of triglyceride lowering in reducing CV risk in patients with T2DM.
Dr. Stephen Wiviott explains how a change in regulatory guidance has dramatically altered the trial landscape and drug development for type 2 diabetes mellitus and has provided substantial information related to CV disease.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients
Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose a drug.
This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017
Prof. Neil Poulter gives a brief overview of the design and results of the LEADER CV outcomes trial with the GLP-1 agonist liraglutide.
This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017
This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017
Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.
Marta Ruiz-Ortega sheds light on the new and exciting field of epigenetics, and how BET inhibition might provide an interesting therapeutic target in renal disease. She shares experimental data dat demonstrate the beneficial effects of BET inhibition.
Luis M Ruilope, MD looks at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.
Invitation by Prof Peter Sever to attend the Clinical Dialogue on Lipids & Diabetes to be held on December 6 & 7 in Stratford Upon Avon, United Kingdom
VBWG ACC 2017 Dr. Rajagopalan considers how the emergence of GLP-1 agonists, DPP-4 inhibitors and SGLT2 inhibitors has caused a sea change in the mangement of diabetes towards a broader approach to address CV risk.
Diabetes and renal dysfunction are very common in patients with heart failure. Prof. Martin Cowie discusses the relationship and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.
Diabetes and diabetic kidney disease are associated with increased risk of cardiovascular disease and remarkably shortened life expectancy. Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.
Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist. The SGLT2 inhibitor empagliflozin, for example, shows both cardiovascular and renal protection, in addition to lowering glucose.
Dr. Jorge Plutzky, MD, discusses the ability to modulate and modify CV risk with new antidiabetic agents. The use of an SGLT2 inhibitor or a GLP1 agonist should be considered in appropriate patients with diabetes.
CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi, including what the results may mean for the management of diabetes.
David Fitchett discusses the CV benefits of the EMPA-REG OUTCOME trial in detail, and considers the possible underlying mechanisms, and whether other patient populations may also benefit.
Michael Mark proposes a new hypothesis that may explain the observed CV benefit of empagliflozin, involving increased haematocrit and higher ketone bodies as a potent alternative energy source.
Richard Pratley takes a close look at the different pharmacological properties of DPP4 inhibitors, and how these may explain why they may be suitable in special patient groups.
Dr. Per-Henrik Groop outlines that diabetic kidney disease is common and associated with a grim prognosis. Optimal glucose control is central to limiting the risk of renal complications. Newer antidiabetic drugs can play a welcome role to optimally treat these patients.
Dr. David Fitchett recalls the history of outcome trials of antidiabetic drugs, culminating in the clear CV benefit obtained with an SGLT2 inhibitor recently shown in the EMPA-REG OUTCOME trial.
Michael Mark illustrates the full trajectory of development of the SGLT2 inhibitor empagliflozin, from finding a therapeutic target through testing clinical effects of the newly developed therapeutic agent.
Richard E. Pratley elaborates on the mechanisms of action, effects and outcomes of the many different classes of antidiabetic drugs that are currently available, and how they can be combined to maximise their effect.
Chaicharn Deerochanawong, MD (Bangkok, Thailand) elaborates on aspects of the diabetes phenotype that are different in Asia, as compared with the rest of the world. These differences affect management of diabetes patients.
John McMurray, MD, describes how SGLT2 inhibitors may work in preventing heart failure in diabetes.
Silvio Inzucchi reviews the role of new medications for diabetes, and in particular the SGLT2 inhibitors, and the results of the EMPA-REG OUTCOMR study
ESC 2016 There are several treatment targets for patients with diabetes and high CV risk. Kausik Ray gives an overview of treatment targets and introduces BET-inhibition as a novel treatment target.
Good glycaemic control can now be achieved with a lower risk of hypoglycaemia than before. Prof. Groop elaborates on the evidence on whether improving glycaemic control with DPP-4 inhibitors translates into a reduction of renal complications.
Recent outcome studies have shown evidence for a CV benefit with novel antidiabetic therapies such as DPP4 inhibitors and SGLT2 inhibitors. Dr. Pratley summarises the observations and speculates on how these findings may affect treatment of patients with diabetes in the near future.
Very recently, data became available of use of the SGLT2-inhibitor empagliflozin in patients with diabetic kidney disease, a condition associated with increased risk of CV complications. Prof. Groop shares the data that suggest that empagliflozin can reduce or prevent the onset of this condition.
Recent outcome trials of novel antidiabetic drugs shed new light on why diabetes patients develop heart disease. Naveed Sattar predicts how this may change diabetes management.
ESC HF 2016 Conventional therapies to treat hyperkalemia are associated with clinical complications. Peter van der Meer discusses the mechanism and efficacy and safety results of two new therapeutic options that lower potassium levels: patiromer and ZS-9.
ESC HF 2016 David Fitchett discusses the results of the EMPA-REG OUTCOME trial: the first published trial evaluating CV endpoints with an SGLT2 inhibitor.
ESC HF 2016 Patients with both HF and diabetes have poor prognosis. Adriaan Voors reviews which currently available therapies provide benefit and which may increase risk in these patients.
Silvio Inzucchi summarises recent developments in treatment of type 2 diabetes. Some new agents yield clear CV event risk reduction, while older glucose-lowering medication only had a moderate effect on CV events.
Dr Fitchett provides his perspective on the potential impact of the EMPA REG outcomes trial on the management of T2DM by cardiologists.
Prof Lambers Heerspink reviews potential mechanisms beyond glucose lowering, explaining the positive cardiovascular outcomes of SGLT2 inhibition as seen in the EMPA REG Outcomes trial.
Dr Rajagopalan, MD, Maryland, USA reviews the utility of DPP4 inhibitors in T2DM patients with high CVD risk.
Dr. Robert Chilton, (Texas) discusses the results of the IRIS trial where treatment with PPAR-γ agonist pioglitazone
Aruna Pradhan (Boston, MA, USA) shows why residual risk is substantial in diabetic patients, despite statin therapy, and considers how this may be targeted by modifying triglyceride levels and/or the PPAR pathway.
The REACH registry demonstrated that CV risk factors are not adequately controlled worldwide. Prof. Deepak Bhatt (Boston, MA, USA) shares the evidence for preventive strategies and considers how the new PCSK9 inhibitors fit into CV risk management.
Prof Stephen Wiviott (Boston, MA, USA) summarises recent advances in development of antidiabetic agents that not only lower glucose but also reduce CV events.
In response to a requirement of regulatory bodies for antidiabetic trials to now include CV outcomes assessment, data of 5 such outcomes trials are now available. Dr. McGuire (Dallas, TX, USA) summarises the results.
A mechanism of action animation of SGLT2-inhibition, a diabetes therapy that directly targets glucose by reducing renal glucose reabsorption, independently of beta cell function and insulin resistance
AHA 2015 Prof. Silvio Inzucchi (Yale Diabetes Center, New Haven, CT, USA) presented the HF outcomes on the large CV outcome EMPA-REG OUTCOME trial, which evaluated treatment with SGLT2-inhibitor empagliflozin in patients with diabetes.
Dr Fitchett discusses the unmet glycemic control needs, the ongoing clinical trials with SGLT2 inhibitors and the EMPA-REG OUTCOME trial
Prof Inzucchi provides an overview on SGLT2 inhibition, how they work and what are the potential pathways for cardiovascular benefits
Prof John Betteridge reviews the rationale for cardiovascular risk factor management in diabetes
Prof Deanfield discusses the rationale for glucose control and CV risk reduction
Dr. Inzucchi, New Haven, provides his perspective on current diabetes therapies and ongoing trials with DPP4 and SGLT2 inhibitors on cardiovascular safety and/or benefits
Prof. Naveed Sattar, Glasgow, UK provides his view on the potential role of novel diabetes drugs in CV risk management
Lecture held by Prof Naveed Sattar, MD, Glasgow, United Kingdom on 'Diabetes and reducing CVD: Are novel interventions living up to their promise?' held during the PACE 2014 Snapshot session in Barcelona
Dr. Boris Mankovsky, Kiev, Ukrain describes the importance to address neurological complications in patients with diabetes, such as diabetic neuropathy, brain damage and stroke.
Dr. Deepak Bhatt reviews trials evaluating the cardiovascular safety of new diabetes drugs such as DPP4 and GLP1 agonists.
Prof John Betteridge reviews the impact of various diabetic drugs on glycemic control, vascular prevention and Beta cell function.
Prof.John Betteridge with a critical appraisal of the results of the HPS2-THRIVE trial and the relevance for clinical practice and design of future outcome trials
Dr. Richard Shannon, Pennsylvania, recognizes that Diabetes is a CVD equivalent and focuses on the importance that incretins can play in improving hemodynamics and outcomes in Heart Failure.
Dr Michael Lincoff, Cleveland Clinic, about the potential for dual PPAR agonists in targeting excess CV risk in diabetes
Prof. Bernard Charbonell (University of Nantes, France) discussed new options in diabetes management.
Prof. E. Standl, Munich discusses the use of practice surveys to guideline recommendations to assess the potential for improvement in real-life.
In this expert interview Professor Sir Alberti discusses why the epidemic rise in T2DM persists despite the availability of medicines.
as a cardiovascular disease Prof John Betteridge, London, discusses the evolution of diabetes therapy, the epidemic rise in diabetes, current and emerging diabetes therapies.
In this expert opinion prof. Guntram Schernthaner discusses the optimal target value of HbA1c, in diabetes or if combined with cardiovascular disease or renal impairment.
Prof. Gordon McInnes , Glasgow, is discussing the optimal approach and targets for blood pressure reduction in CV risk and diabetes
Opportunities for lipid management, Ronald Ma, MD, The Chinese University of Hong Kong, in discussion with prof John Deanfield
**Prof Mark Kearney, cardiogist, University of Leeds, UK, in discussion with Prof John Betteridge** the current opinions and perspectives on the use of TZD’s in type 2 diabetes & CV Risk.
**Dr Stephen Lawrence GP, St Mary's Island, CHATHAM KENT, UK, in discussion with Prof John Betteridge** the current opinions and perspectives on the use of TZD’s in type 2 diabetes & CV Risk.
Dr John Reckless , Consultant Endocrinologist, University of Bath, UK, in discussion with Prof John Betteridge the current opinions and perspectives on the use of TZD’s in type 2 diabetes & CV Risk.
**in Asia; Do they need a different approach in management? **Prof. John Betteridge UCL, London United Kingdom
**Asia: The Management of CV risk in diabetes and the metabolic syndrome **Dr David Waters San Francisco General Hospital, California, USA, June 2009, VBG Asia
**Exploring New Insights in Diabetes & Cardiovascular disease **Prof John Deanfield & Prof John Betteridge University College London Directors PACE foundation
**Sustained Glycemic control in (Pre) diabetes What and how is te best time to act? **Prof. Bernard Charbonnel University of Nantes, France
**Managing hypertension to protect the diabetic patient: When and how to intervene? **Prof. Tom MacDonald University of Dundee, United Kingdom
**New opportunities for ARBs: Interventions in the course of CV risk & diabetes **Prof. Gordon McInnes, the The Western Infirmary, Glasgow, United Kingdom
**Are fixed dose therapies the solution to optimal care? **Prof Guntram Schernthaner, Rudolfstiftung Hospital, Vienna, Austria